Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Cancer
Interventions: DRUG: Lapatinib|BIOLOGICAL: Trastuzumab
Sponsor: Novartis Pharmaceuticals